
Soligenix, Inc. (NASDAQ:SNGX) stock is higher on Monday after the U.S. Food and Drug Administration granted orphan drug designation to dusquetide, the active ingredient in SGX945, for Behçet’s Disease.
Follow SNGX stock’s rise today here.

Soligenix, Inc. (NASDAQ:SNGX) stock is higher on Monday after the U.S. Food and Drug Administration granted orphan drug designation to dusquetide, the active ingredient in SGX945, for Behçet’s Disease.
Follow SNGX stock’s rise today here.